Irinotecan Plus Anlotinib or Further in Combination With Piamprizumab for Second-line Treatment of mCRC
Status:
Not yet recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This is an exploratory, non-controlled, multi-cohort, phase II small-sample clinical study
designed to evaluate the clinical benefit of second-line treatment with anrotinib plus
irinotecan or further in combination with a PD-1 monoclonal antibody (piamprizumab) in
patients with advanced colorectal cancer after first-line treatment failure. To explore the
rationality of the combination of chemotherapy and targeted therapy and immunotherapy
strategy and obtain relevant survival and safety data. The study will fully evaluate the
efficacy, PFS, OS, safety and related biomarkers of the regimen.